← Russell 3000 cross-section

COO COOPER COMPANIES, INC.

Trailing twelve months to 2026-04-30 · as filed 2026-06-05, not restated
Healthcare

Scale

Market cap
$14.0bn
Revenue TTM
$4.2bn
Net income TTM
$236m
Free cash flow
$570m
Composite score
47.0
Sector rank
#569

Valuation

P / E
59.3
EV / EBITDA
18.5
EV / sales
3.9
FCF yield
4.07%
Earnings yield vs 10-yr
-3.04pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
5.6%
EBITDA margin
20.9%
ROE
2.9%
ROIC
4.7%
Revenue growth
6.1%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Management’s Discussion and Analysis of Financial Condition and Results of Operations In the three and six months ended April 30, 2026, the growth experienced across all categories was positively impacted by favorable foreign exchange rate fluctuations of approximately $28.4 million and $56.5 million, respectively. • Toric and multifocal grew primarily through the success of Biofinity and MyDay. • Sphere, other grew primarily through MyDay and MiSight. • "Other" products represented less than 1% of net sales in the three and six months ended April 30, 2026 and 2025, respectively. …COOPER COMPANIES, INC., 10-Q, period ended 2026-04-30, filed 2026-06-05

Read the full passage →